Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?

Cell Metabolism

Volumn 25, Issue 2, 2017, Pages 233-241

  Kolb, Hubert ^a,b   von Herrath, Matthias ^c,d  

^a Dusseldorf Catholic Hospital Group   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE; CELL DESTRUCTION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; ANIMAL; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; IMMUNOLOGY; METABOLISM; PANCREAS ISLET BETA CELL; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; TREATMENT OUTCOME;

EID: 85006274258     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.10.009     Document Type: Note

References (88)

1. Allen, H.F., Klingensmith, G.J., Jensen, P., Simoes, E., Hayward, A., Chase, H.P., Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes Care 22 (1999), 1703–1707.
2. Ambery, P., Donner, T.W., Biswas, N., Donaldson, J., Parkin, J., Dayan, C.M., Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet. Med. 31 (2014), 399–402.
3. Askenasy, N., Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes. Int. Rev. Immunol. 34 (2015), 523–537.
4. Assan, R., Feutren, G., Debray-Sachs, M., Quiniou-Debrie, M.C., Laborie, C., Thomas, G., Chatenoud, L., Bach, J.F., Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1 (1985), 67–71.
5. Atkinson, M.A., von Herrath, M., Powers, A.C., Clare-Salzler, M., Current concepts on the pathogenesis of type 1 diabetes—considerations for attempts to prevent and reverse the disease. Diabetes Care 38 (2015), 979–988.
6. Bao, M., Yang, Y., Jun, H.S., Yoon, J.W., Molecular mechanisms for gender differences in susceptibility to T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol. 168 (2002), 5369–5375.
7. Baumgart, D.C., Carding, S.R., Inflammatory bowel disease: cause and immunobiology. Lancet 369 (2007), 1627–1640.
8. Brown, P.M., Isaacs, J.D., Rheumatoid arthritis: from palliation to remission in two decades. Clin. Med. (Lond.) 14:Suppl 6 (2014), s50–s55.
9. Burkart, V., Kim, Y.E., Hartmann, B., Ghiea, I., Syldath, U., Kauer, M., Fingberg, W., Hanifi-Moghaddam, P., Müller, S., Kolb, H., Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide. J. Immunol. 168 (2002), 1730–1737.
10. Burke, G.W. 3rd, Vendrame, F., Virdi, S.K., Ciancio, G., Chen, L., Ruiz, P., Messinger, S., Reijonen, H.K., Pugliese, A., Lessons from pancreas transplantation in type 1 diabetes: recurrence of islet autoimmunity. Curr. Diab. Rep., 15, 2015, 121.
11. Campbell-Thompson, M., Fu, A., Kaddis, J.S., Wasserfall, C., Schatz, D.A., Pugliese, A., Atkinson, M.A., Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes 65 (2016), 719–731.
12. Cárdenas-Roldán, J., Rojas-Villarraga, A., Anaya, J.M., How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med., 11, 2013, 73.
13. Chamberlain, N., Massad, C., Oe, T., Cantaert, T., Herold, K.C., Meffre, E., Rituximab does not reset defective early B cell tolerance checkpoints. J. Clin. Invest. 126 (2016), 282–287.
14. Chmelova, H., Cohrs, C.M., Chouinard, J.A., Petzold, C., Kuhn, M., Chen, C., Roeder, I., Kretschmer, K., Speier, S., Distinct roles of β-cell mass and function during type 1 diabetes onset and remission. Diabetes 64 (2015), 2148–2160.
15. Dai, Y., Dai, D., Wang, X., Ding, Z., Mehta, J.L., DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc. Drugs Ther. 28 (2014), 425–432.
16. de Beeck, A.O., Eizirik, D.L., Viral infections in type 1 diabetes mellitus—why the β cells?. Nat. Rev. Endocrinol. 12 (2016), 263–273.
17. Dendrou, C.A., Fugger, L., Friese, M.A., Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15 (2015), 545–558.
18. Diaz-Valencia, P.A., Bougnères, P., Valleron, A.J., Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health, 15, 2015, 255.
19. DiMeglio, L.A., Cheng, P., Beck, R.W., Kollman, C., Ruedy, K.J., Slover, R., Aye, T., Weinzimer, S.A., Bremer, A.A., Buckingham, B., Diabetes Research in Children Network (DirecNet); Type 1 Diabetes TrialNet Study Group. Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. Pediatr. Diabetes 17 (2016), 237–243.
20. Ding, L., Gysemans, C.A., Stangé, G., Heremans, Y., Yuchi, Y., Takiishi, T., Korf, H., Chintinne, M., Carr, R.D., Heimberg, H., et al. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice. PLoS ONE, 9, 2014, e107935.
21. Dooley, J., Tian, L., Schonefeldt, S., Delghingaro-Augusto, V., Garcia-Perez, J.E., Pasciuto, E., Di Marino, D., Carr, E.J., Oskolkov, N., Lyssenko, V., et al. Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes. Nat. Genet. 48 (2016), 519–527.
22. Foulis, A.K., Liddle, C.N., Farquharson, M.A., Richmond, J.A., Weir, R.S., The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29 (1986), 267–274.
23. Garyu, J.W., Uduman, M., Stewart, A., Rui, J., Deng, S., Shenson, J., Staron, M.M., Kaech, S.M., Kleinstein, S.H., Herold, K.C., Characterization of diabetogenic CD8+ T cells: immune therapy with metabolic blockade. J. Biol. Chem. 291 (2016), 11230–11240.
24. Giovannoni, G., Turner, B., Gnanapavan, S., Offiah, C., Schmierer, K., Marta, M., Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Mult. Scler. Relat. Disord. 4 (2015), 329–333.
25. Gitelman, S.E., Gottlieb, P.A., Rigby, M.R., Felner, E.I., Willi, S.M., Fisher, L.K., Moran, A., Gottschalk, M., Moore, W.V., Pinckney, A., et al., START Study Team. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 1 (2013), 306–316.
26. Grigor, C., Capell, H., Stirling, A., McMahon, A.D., Lock, P., Vallance, R., Kincaid, W., Porter, D., Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004), 263–269.
27. Gruessner, R.W., Gruessner, A.C., Pancreas transplant alone: a procedure coming of age. Diabetes Care 36 (2013), 2440–2447.
28. Gruessner, R.W., Pugliese, A., Reijonen, H.K., Gruessner, S., Jie, T., Desai, C., Sutherland, D.E., Burke, G.W. 3rd, Development of diabetes mellitus in living pancreas donors and recipients. Expert Rev. Clin. Immunol. 7 (2011), 543–551.
29. Hinman, R.M., Smith, M.J., Cambier, J.C., B cells and type 1 diabetes …in mice and men. Immunol. Lett. 160 (2014), 128–132.
30. Hwang, H.J., Chung, H.S., Jung, T.W., Ryu, J.Y., Hong, H.C., Seo, J.A., Kim, S.G., Kim, N.H., Choi, K.M., Choi, D.S., et al. The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms. Mol. Cell. Endocrinol. 405 (2015), 25–34.
31. In't Veld, P., Insulitis in human type 1 diabetes: a comparison between patients and animal models. Semin. Immunopathol. 36 (2014), 569–579.
32. Insel, R.A., Dunne, J.L., Atkinson, M.A., Chiang, J.L., Dabelea, D., Gottlieb, P.A., Greenbaum, C.J., Herold, K.C., Krischer, J.P., Lernmark, Å., et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38 (2015), 1964–1974.
33. Jalleh, R.P., Williamson, R.C., Pancreatic exocrine and endocrine function after operations for chronic pancreatitis. Ann. Surg. 216 (1992), 656–662.
34. Jutley, G., Raza, K., Buckley, C.D., New pathogenic insights into rheumatoid arthritis. Curr. Opin. Rheumatol. 27 (2015), 249–255.
35. Keymeulen, B., Walter, M., Mathieu, C., Kaufman, L., Gorus, F., Hilbrands, R., Vandemeulebroucke, E., Van de Velde, U., Crenier, L., De Block, C., et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53 (2010), 614–623.
36. Kolb, H., Eizirik, D.L., Resistance to type 2 diabetes mellitus: a matter of hormesis?. Nat. Rev. Endocrinol. 8 (2011), 183–192.
37. Kolb, H., Gale, E.A., Does partial preservation of residual beta-cell function justify immune intervention in recent onset Type I diabetes?. Diabetologia 44 (2001), 1349–1353.
38. Krogvold, L., Skog, O., Sundström, G., Edwin, B., Buanes, T., Hanssen, K.F., Ludvigsson, J., Grabherr, M., Korsgren, O., Dahl-Jørgensen, K., Function of Isolated Pancreatic Islets From Patients at Onset of Type 1 Diabetes: Insulin Secretion Can Be Restored After Some Days in a Nondiabetogenic Environment In Vitro: Results From the DiViD Study. Diabetes 64 (2015), 2506–2512.
39. Lampeter, E.F., Homberg, M., Quabeck, K., Schaefer, U.W., Wernet, P., Bertrams, J., Grosse-Wilde, H., Gries, F.A., Kolb, H., Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 341 (1993), 1243–1244.
40. Lampeter, E.F., McCann, S.R., Kolb, H., Transfer of diabetes type 1 by bone-marrow transplantation. Lancet 351 (1998), 568–569.
41. Lebwohl, B., Ludvigsson, J.F., Green, P.H., Celiac disease and non-celiac gluten sensitivity. BMJ, 351, 2015, h4347.
42. Liu, X., Nemeth, D.P., Tarr, A.J., Belevych, N., Syed, Z.W., Wang, Y., Ismail, A.S., Reed, N.S., Sheridan, J.F., Yajnik, A.R., et al. Euflammation attenuates peripheral inflammation-induced neuroinflammation and mitigates immune-to-brain signaling. Brain Behav. Immun. 54 (2016), 140–148.
43. Ludvigsson, J., Therapies to preserve β-cell function in type 1 diabetes. Drugs 76 (2016), 169–185.
44. Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castaño, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.J., et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N. Engl. J. Med. 366 (2012), 433–442.
45. Marshall, R., Taylor, I., Lahr, C., Abell, T.L., Espinoza, I., Gupta, N.K., Gomez, C.R., Bioelectrical stimulation for the reduction of inflammation in inflammatory bowel disease. Clin. Med. Insights Gastroenterol. 8 (2015), 55–59.
46. Martin, S., Pawlowski, B., Greulich, B., Ziegler, A.G., Mandrup-Poulsen, T., Mahon, J., Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 15 (1992), 66–74.
47. Martin, S., Wolf-Eichbaum, D., Duinkerken, G., Scherbaum, W.A., Kolb, H., Noordzij, J.G., Roep, B.O., Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med. 345 (2001), 1036–1040.
48. Mastrandrea, L., Yu, J., Behrens, T., Buchlis, J., Albini, C., Fourtner, S., Quattrin, T., Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32 (2009), 1244–1249.
49. McNamee, K., Williams, R., Seed, M., Animal models of rheumatoid arthritis: How informative are they?. Eur. J. Pharmacol. 759 (2015), 278–286.
50. Menge, B.A., Breuer, T.G., Ritter, P.R., Uhl, W., Schmidt, W.E., Meier, J.J., Long-term recovery of β-cell function after partial pancreatectomy in humans. Metabolism 61 (2012), 620–624.
51. Moran, A., Bundy, B., Becker, D.J., DiMeglio, L.A., Gitelman, S.E., Goland, R., Greenbaum, C.J., Herold, K.C., Marks, J.B., Raskin, P., et al. Type 1 Diabetes TrialNet Canakinumab Study Group, AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381 (2013), 1905–1915.
52. Morris, D.L., Minireview: emerging concepts in islet macrophage biology in type 2 diabetes. Mol. Endocrinol. 29 (2015), 946–962.
53. Nam, J.L., Rheumatoid arthritis management of early disease. Curr. Opin. Rheumatol. 28 (2016), 267–274.
54. National Clinical Guideline Centre (UK). Multiple Sclerosis: Management of Multiple Sclerosis in Primary and Secondary Care. No. 186, 2014, National Institute for Health and Care Excellence [UK].
55. Nguyen, L.K., Cavadas, M.A., Kholodenko, B.N., Frank, T.D., Cheong, A., Species differential regulation of COX2 can be described by an NFκB-dependent logic AND gate. Cell. Mol. Life Sci. 72 (2015), 2431–2443.
56. Nielsen, N.M., Westergaard, T., Frisch, M., Rostgaard, K., Wohlfahrt, J., Koch-Henriksen, N., Melbye, M., Hjalgrim, H., Type 1 diabetes and multiple sclerosis: a Danish population-based cohort study. Arch. Neurol. 63 (2006), 1001–1004.
57. Nikulina, M., Habich, C., Flohé, S.B., Scott, F.W., Kolb, H., Wheat gluten causes dendritic cell maturation and chemokine secretion. J. Immunol. 173 (2004), 1925–1933.
58. Noble, J.A., Immunogenetics of type 1 diabetes: a comprehensive review. J. Autoimmun. 64 (2015), 101–112.
59. O'Neill, L.A., Pearce, E.J., Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 213 (2016), 15–23.
60. Onengut-Gumuscu, S., Chen, W.M., Burren, O., Cooper, N.J., Quinlan, A.R., Mychaleckyj, J.C., Farber, E., Bonnie, J.K., Szpak, M., Schofield, E., et al., Type 1 Diabetes Genetics Consortium. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat. Genet. 47 (2015), 381–386.
61. Orban, T., Bundy, B., Becker, D.J., Dimeglio, L.A., Gitelman, S.E., Goland, R., Gottlieb, P.A., Greenbaum, C.J., Marks, J.B., Monzavi, R., et al., Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37 (2014), 1069–1075.
62. Palm, N.W., de Zoete, M.R., Flavell, R.A., Immune-microbiota interactions in health and disease. Clin. Immunol. 159 (2015), 122–127.
63. Pearson, J.A., Wong, F.S., Wen, L., The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. J. Autoimmun. 66 (2016), 76–88.
64. Pescovitz, M.D., Greenbaum, C.J., Bundy, B., Becker, D.J., Gitelman, S.E., Goland, R., Gottlieb, P.A., Marks, J.B., Moran, A., Raskin, P., et al., Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care 37 (2014), 453–459.
65. Pipeleers, D.G., Heterogeneity in pancreatic beta-cell population. Diabetes 41 (1992), 777–781.
66. Procaccini, C., De Rosa, V., Pucino, V., Formisano, L., Matarese, G., Animal models of Multiple Sclerosis. Eur. J. Pharmacol. 759 (2015), 182–191.
67. Rekers, N.V., von Herrath, M.G., Wesley, J.D., Immunotherapies and immune biomarkers in Type 1 diabetes: A partnership for success. Clin. Immunol. 161 (2015), 37–43.
68. Rigby, M.R., DiMeglio, L.A., Rendell, M.S., Felner, E.I., Dostou, J.M., Gitelman, S.E., Patel, C.M., Griffin, K.J., Tsalikian, E., Gottlieb, P.A., et al., T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 1 (2013), 284–294.
69. Robertson, R.P., Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes 53 (2004), 633–644.
70. Rodriguez-Calvo, T., Suwandi, J.S., Amirian, N., Zapardiel-Gonzalo, J., Anquetil, F., Sabouri, S., von Herrath, M.G., Heterogeneity and lobularity of pancreatic pathology in type 1 diabetes during the prediabetic phase. J. Histochem. Cytochem. 63 (2015), 626–636.
71. Saxena, A., Khosraviani, S., Noel, S., Mohan, D., Donner, T., Hamad, A.R., Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74 (2015), 27–34.
72. Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S.M., Wahlen, J., Ferry, R.J. Jr., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al., Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378 (2011), 487–497.
73. Shinjo, T., Nakatsu, Y., Iwashita, M., Sano, T., Sakoda, H., Ishihara, H., Kushiyama, A., Fujishiro, M., Fukushima, T., Tsuchiya, Y., et al. DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation. Am. J. Physiol. Endocrinol. Metab. 309 (2015), E214–E223.
74. Sims, E.K., Chaudhry, Z., Watkins, R., Syed, F., Blum, J., Ouyang, F., Perkins, S.M., Mirmira, R.G., Sosenko, J., DiMeglio, L.A., Evans-Molina, C., Elevations in the fasting serum proinsulin-to-C-peptide ratio precede the onset of type 1 diabetes. Diabetes Care 39 (2016), 1519–1526.
75. Singh, J.A., Saag, K.G., Bridges, S.L. Jr., Akl, E.A., Bannuru, R.R., Sullivan, M.C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R.H., et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68 (2016), 1–26.
76. Smith, S.M., Freeley, M., Moynagh, P.N., Kelleher, D.P., Differential modulation of Helicobacter pylori lipopolysaccharide-mediated TLR2 signaling by individual Pellino proteins. Helicobacter, 2016 Published online June 15, 2016.
77. Stanescu, D.E., Lord, K., Lipman, T.H., The epidemiology of type 1 diabetes in children. Endocrinol. Metab. Clin. North Am. 41 (2012), 679–694.
78. Sun, J.B., Czerkinsky, C., Holmgren, J., Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand. J. Immunol. 71 (2010), 1–11.
79. Sutherland, D.E., Moudry, K.C., Fryd, D.S., Results of pancreas-transplant registry. Diabetes 38:Suppl 1 (1989), 46–54.
80. Tanaka, M., Matsuo, Y., Yamakage, H., Masuda, S., Terada, Y., Muranaka, K., Wada, H., Hasegawa, K., Shimatsu, A., Satoh-Asahara, N., Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects. Metabolism 65 (2016), 1–11.
81. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37 (1988), 1574–1582.
82. Todd, J.A., Intolerable secretion and diabetes in tolerant transgenic mice, revisited. Nat. Genet. 48 (2016), 476–477.
83. Tramacere, I., Del Giovane, C., Salanti, G., D'Amico, R., Filippini, G., Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst. Rev., 9, 2015, CD011381.
84. Vendrame, F., Hopfner, Y.Y., Diamantopoulos, S., Virdi, S.K., Allende, G., Snowhite, I.V., Reijonen, H.K., Chen, L., Ruiz, P., Ciancio, G., et al. Risk factors for type 1 diabetes recurrence in immunosuppressed recipients of simultaneous pancreas-kidney transplants. Am. J. Transplant. 16 (2016), 235–245.
85. von Herrath, M., Peakman, M., Roep, B., Progress in immune-based therapies for type 1 diabetes. Clin. Exp. Immunol. 172 (2013), 186–202.
86. Welsh, N., Margulis, B., Borg, L.A., Wiklund, H.J., Saldeen, J., Flodström, M., Mello, M.A., Andersson, A., Pipeleers, D.G., Hellerström, C., et al. Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependent diabetes mellitus. Mol. Med. 1 (1995), 806–820.
87. Wherrett, D.K., Bundy, B., Becker, D.J., DiMeglio, L.A., Gitelman, S.E., Goland, R., Gottlieb, P.A., Greenbaum, C.J., Herold, K.C., Marks, J.B., et al., Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378 (2011), 319–327.
88. Ziemssen, T., De Stefano, N., Pia Sormani, M., Van Wijmeersch, B., Wiendl, H., Kieseier, B.C., Optimizing therapy early in multiple sclerosis: An evidence-based view. Mult. Scler. Relat. Disord. 4 (2015), 460–469.